Company / Free Cash Flow
RAPT Therapeutics, Inc. Free Cash Flow History
FY2018-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$83.4M
FY2024
5-year range
-$98.2M / -$40.9M
FY2020-FY2024
Trend
+15.0%
vs FY2023
Sector context
#102 of 195
Health Care
What the data says
At -$83M, RAPT Therapeutics, Inc.'s free cash flow ranks #102 of 195 in the Health Care sector. Free Cash Flow returned to growth in FY2024 after 4 years of decline, reaching -$83M.
Based on SEC 10-K filings.
-$83M in FY2024.
Declined from -$72M to -$83M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#102 of 195 in Health CareTop 52% of 195This company -$83.4M Sector average $465.6M
▼
-117.9% below sector average
Key checks
Key Insights
- In FY2024, free cash flow increased 15.0% year-over-year.
- Ranks #102 out of 195 companies in the Health Care sector.
- Peak free cash flow was recorded in FY2019.
- Lowest free cash flow in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.38 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$83.4M | +15.0% |
| FY2023 | -$98.2M | -37.1% |
| FY2022 | -$71.6M | -15.9% |
| FY2021 | -$61.8M | -51.1% |
| FY2020 | -$40.9M | -12.4% |
| FY2019 | -$36.4M | +0.2% |
| FY2018 | -$36.5M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026